Biotechnology

Sionna Therapeutics

Sionna Therapeutics released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5999 (forecast USD -0.5155)

Sionna Therapeutics released FY2025 Annual Earnings on March 2, 2026 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -1.8834 (forecast USD -2.0277)

Sionna Therapeutics released FY2025 Q4 earnings on March 2, 2026 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4579 (forecast USD -0.5466)

Dr. Cory Jubinville Initiates Buy Rating on Sionna Therapeutics

Sionna Therapeutics Chief Legal Officer Reports Disposition of Common Stock

BTIG Maintains Buy Rating on Sionna Therapeutics, Inc.

RA Capital Management Disposes of Sionna Therapeutics Common Stock

BTIG Predicts a Glorious 2026 for Biotech Sector, Recommends Multiple Stocks

Sionna Therapeutics Reports Q3 Earnings and Launches Clinical Trials

Sionna Therapeutics released FY2025 Q3 earnings on November 5, 2025 (EST), with actual EPS of USD -0.4582 (forecasted USD -0.4933)

Sionna Therapeutics released FY2025 9 Months earnings on November 5, 2025 (EST), actual revenue USD 0, actual EPS USD -1.4892

Sionna Therapeutics released FY2024 Q3 earnings on November 5, 2025 (EST), actual revenue USD 0, actual EPS USD -5.6714

Sionna Therapeutics released FY2024 9 Months Earnings on November 5, 2025 (EST), actual revenue USD 0, actual EPS USD -12.221

Sionna Therapeutics Reports Positive Phase 1 Results for NBD1 Stabilizers and Launches Phase 2 Study

Sionna Initiates Clinical Trial for SION-719 to Evaluate Treatment of Cystic Fibrosis

Sionna Therapeutics Reports Positive Phase 1 Clinical Trial Results for New Cystic Fibrosis Drugs

Sionna Therapeutics released FY2024 Semi-Annual Earnings on August 11 (EST), with actual revenue of USD 0 and EPS of USD -6.5355

Sionna Therapeutics released FY2024 Q2 earnings on August 11 (EST) with actual revenue of USD 0 and EPS of USD -2.7064

Sionna Therapeutics released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4095 (forecast USD -0.645)

Sionna Therapeutics released FY2025 Semi-Annual earnings on August 11, 2025, EST with actual revenue USD 0 and EPS USD -0.9758

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SION

LifeSci Capital has reaffirmed a Buy rating on Sionna Therapeutics, Inc. (SION) with a price target of $60.00. Analyst Gaurav Maini has an average return of 12.2% and a 75% success rate. Sionna also received a Buy rating from TD Cowen, while RBC Capital maintained a Sell rating.

Tip Ranks

Tenax Therap

Tectonic Therapeutic

LifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)

RBC Capital's Brian Abrahams has maintained a Sell rating on Sionna Therapeutics, Inc. (SION) with a price target of $23.00, while the stock closed at $40.94. Despite this, the overall analyst consensus for Sionna is a Strong Buy, with an average price target of $52.86. Abrahams has a 10.1% average return and a 51.10% success rate on his stock recommendations.

Gilead Sciences

BioCryst Pharma

Acadia Pharma

RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION)

Kambiz Yazdi from BTIG has reiterated a Buy rating on Sionna Therapeutics, Inc. with a price target of $58.00, citing the company's advancing clinical pipeline and promising data for its lead asset, SION-719. The Phase 2a PreciSION CF trial has completed enrollment, and prior results indicate strong engagement and tolerability. Yazdi emphasizes the significance of reducing sweat chloride levels, with the 2026 readout expected to be a major catalyst. LifeSci Capital also maintains a Buy rating with a $60.00 target.

Zevra Therapeutics

Praxis Precision Medicines

Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 Readout

Sionna Therapeutics (NASDAQ:SION) saw its stock price drop 10.4% to $41.17 following disappointing earnings, reporting a loss of $0.60 per share, missing estimates by $0.08. Approximately 324,024 shares traded, down 6% from average volume. Despite positive developments in clinical trials and a strong cash position, insider selling has raised concerns. Analysts maintain a "Moderate Buy" rating with an average target price of $53.00. Recent insider transactions involved significant share sales under pre-arranged plans, indicating a 6.46% decrease in their holdings.

Market Beat

Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.4% on Disappointing Earnings

Sionna Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.

benzinga_article

Sionna Therapeutics reported its 1Q 2026 results, showing revenue of $27.4M and a net income of $26.78M, with a diluted EPS of $0.6. Compared to the prior year, revenue increased by 65.6%, while net income rose by 62.5%. The company completed Phase 1 trials for SION-719 and SION-451 and is advancing to Phase 2a studies. Sionna maintains $289.9M in liquidity and has an ATM equity program to support operations through 2028.

TradingView

Sionna Therapeutics 1Q 2026: Revenue ($27.4M), Net income ($26.78M), EPS ($0.6) — 10-Q Summary

CCCC

VSTS

On May 12, 2026, several companies are scheduled to report their earnings. Notable projections include Sionna Therapeutics, C4 Therapeutics, and Vestis, with expected earnings and losses varying across the board. For instance, C4 Therapeutics anticipates a loss of $0.25 per share, while Vestis is expected to report earnings of $0.08 per share. Other companies like Under Armour and Sea are also set to report, with Under Armour projected to have a loss of $0.02 per share. Overall, the earnings reports will cover a wide range of sectors and financial outcomes.

- Several companies are projected to report their quarterly earnings and losses before and after the market bell.  
- Notable earnings forecasts include JD.com estimating $0.50 per share with $45.57 billion in revenue, while Sionna Therapeutics and other firms anticipate their first-quarter earnings.  
- Several companies, such as Via Transportation and Under Armour, are expected to report quarterly losses, highlighting a range of financial performance expectations across different sectors.

C4 Therapeutics

Vestis

Under Armour-C

Under Armour

Via Transportation - CL

Arvinas

Opus Genetics

Sleep Number

Veritone

Alliance Laundry

Broadwind

Ralliant

Legend Biotech

Neogenomics

First Majestic Silver

Neuraxis

D-Wave Quantum

Etoro

LightInTheBox

Acumen Pharmaceuticals

Brightstar Lottery

Lithium Americas Argentina C

Cardinal Infrastructure

Zebra Tech

Allot Comm

Aramark

Ampco-Pittsburgh

Vishay Precision

T1 Energy

Venture Global

Qnity Electronics

Ducommun

JD.com

Beta Tech

On Holding AG

Tencent Music

Icecure Medical

NeuroOne Medical Tech

HUYA

RALLIANT CORP

D-WAVE QUANTUM INC C/WTS 05/08/2027 (TO PUR COM)

AMPCO-PITTSBURGH CORP C/WTS 01/08/2025 (TO PUR COM) SER A

T1 ENERGY INC C/WTS 09/07/2026(TO PUR COM)

QNITY ELECTRONICS INC.

JD-SWR

JD-SW

TME-SW

Earnings Scheduled For May 12, 2026

Earnings Watch

Sionna Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

ACRS

KALU

AMAT

BMEA

Top Wall Street analysts have initiated coverage on several companies with varying ratings. Seaport Global's Jay Goldberg rated Applied Materials (AMAT) as Buy with a $500 target. Citizens' Jonathan Wolleben rated Biomea Fusion (BMEA) as Market Outperform with a $9 target. Guggenheim's Seamus Fernandez rated Aclaris Therapeutics (ACRS) as Buy with a $12 target. UBS's Alex Stansbury rated Kaiser Aluminum (KALU) as Neutral with a $176 target. Wedbush's Laura Chico rated Sionna Therapeutics (SION) as Outperform with a $53 target.

Aclaris Therap

Kaiser Aluminum

Applied Materials

Biomea Fusion

Shutterstock

This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Sionna Therapeutics(SION.US)